It’s not surprising there’s a considerable amount of attention being paid to the five different vaccines in late-stage development for COVID-19. Every phase completed is a little victory in a time where wins are few. So when one of the vaccines furthest along, the one being produced in concert by AstraZeneca and Oxford University, had to halt its trials because of a severe adverse effect experienced by one of its U.K. participants, it makes news. 

But that isn’t dire news, according to several life sciences attorneys with experience in the stop-and-go process of biological product development. 

Brian Malkin

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]